Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Contact Information

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

Market Cap

$119.94M

P/E (TTM)

-1.2

22.8

Dividend Yield

52W High

$55.89

52W Low

$5.20

52W Range

14%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 8-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2018-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$1.69+0.00%

4-Quarter Trend

FCF

-$16.10M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Collaboration Revenue Increased Collaboration revenue reached $6.4M USD in 2025, up $4.1M USD from $2.3M USD in 2024, driven by Novo Nordisk agreement.

KRRO-121 Advancement Progressing Lead candidate KRRO-121 targets hyperammonemia with regulatory filing anticipated in the second half of 2026 for first-in-human trial.

AATD Candidate Nomination Nearing Next-generation AATD program expects development candidate nomination in the second quarter of 2026 following pivot to GalNAc delivery.

Cash Runway Extended Cash runway extends into the second half of 2028 supporting key milestones after recent financing activities and restructuring efforts.

Risk Factors

Continued Operating Losses Expected Net loss widened to $(117.3M) USD in 2025 from $(83.6M) USD in 2024; expects increasing expenses and negative cash flow indefinitely.

Significant Asset Impairment Recognized $30.9M USD non-cash impairment charge in Q4 2025 related to operating lease and fixed assets following program termination.

Pipeline Concentration Risk High Business heavily reliant on KRRO-121 success; only nominated candidate after terminating KRRO-110 program due to insufficient functional protein levels.

Novel Technology Unproven RNA editing technology is new with limited clinical validation; preclinical success does not guarantee positive results in human trials.

Outlook

Advance KRRO-121 Clinical Trial Anticipate regulatory filing for KRRO-121 in H2 2026 to commence first-in-human trial for hyperammonemia treatment indications.

Optimize OPERA Platform Further Continue enhancing OPERA platform using computational models and new data to expedite design and optimization of future lead candidates.

Advance ALS and Longevity Programs Continue advancing ALS program targeting TDP-43 aggregation and longevity program targeting AMPKγ1 activation through preclinical studies.

Seek Strategic Partnerships Plan to actively seek innovative collaborations and strategic alliances to maximize OPERA platform potential across rare and prevalent diseases.

Peer Comparison

Revenue (TTM)

AMRN

$214.88M

+0.3%

ADCT

$79.18M

+4.4%

AUTL

$75.35M

+644.6%

Gross Margin (Latest Quarter)

ALT

100.0%

-299200.0pp

SLN

97.4%

+202.7pp

ADCT

82.7%

-2.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$680.50M	-5.6	-101.2%	9.7%
AURA	$539.28M	-4.8	-71.2%	10.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 19, 2026

EPS:-$1.73

Revenue:$761.17K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data